94 related articles for article (PubMed ID: 11794258)
1. Clinical significance of P-glycoprotein immunohistochemistry and doxorubicin binding assay in patients with osteosarcoma.
Kumta SM; Zhu QS; Lee KM; Griffith J; Chow LT; Leung PC
Int Orthop; 2001; 25(5):279-82. PubMed ID: 11794258
[TBL] [Abstract][Full Text] [Related]
2. Relationship between P-glycoprotein positivity, doxorubicin binding ability and histologic response to chemotherapy in osteosarcomas.
Kusuzaki K; Hirata M; Takeshita H; Murata H; Hashiguchi S; Ashihara T; Hirasawa Y
Cancer Lett; 1999 Apr; 138(1-2):203-8. PubMed ID: 10378794
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy.
Chan HS; Grogan TM; Haddad G; DeBoer G; Ling V
J Natl Cancer Inst; 1997 Nov; 89(22):1706-15. PubMed ID: 9390540
[TBL] [Abstract][Full Text] [Related]
4. [P-glycoprotein expression in osteosarcoma].
Pösl M; Grahl K; Amling M; Werner M; Ritzel H; Stenzel I; Hentz M; Winkler K; Delling G
Pathologe; 1996 Jan; 17(1):50-5. PubMed ID: 8685096
[TBL] [Abstract][Full Text] [Related]
5. Assessment of chemosensitivity in patients with osteogenic sarcoma using the doxorubicin binding assay.
Kumta SM; Leung PC; Chow L; To SH; Lee S; Cheng SH
J Surg Oncol; 1998 Jul; 68(3):169-72. PubMed ID: 9701209
[TBL] [Abstract][Full Text] [Related]
6. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.
Serra M; Scotlandi K; Reverter-Branchat G; Ferrari S; Manara MC; Benini S; Incaprera M; Bertoni F; Mercuri M; Briccoli A; Bacci G; Picci P
J Clin Oncol; 2003 Feb; 21(3):536-42. PubMed ID: 12560446
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy.
Baldini N; Scotlandi K; Serra M; Picci P; Bacci G; Sottili S; Campanacci M
J Orthop Res; 1999 Sep; 17(5):629-32. PubMed ID: 10569469
[TBL] [Abstract][Full Text] [Related]
8. Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines.
Takeshita H; Gebhardt MC; Springfield DS; Kusuzaki K; Mankin HJ
J Bone Joint Surg Am; 1996 Mar; 78(3):366-75. PubMed ID: 8613443
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein levels predict poor outcome in patients with osteosarcoma.
Hornicek FJ; Gebhardt MC; Wolfe MW; Kharrazi FD; Takeshita H; Parekh SG; Zurakowski D; Mankin HJ
Clin Orthop Relat Res; 2000 Apr; (373):11-7. PubMed ID: 10810457
[TBL] [Abstract][Full Text] [Related]
10. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol.
Serra M; Pasello M; Manara MC; Scotlandi K; Ferrari S; Bertoni F; Mercuri M; Alvegard TA; Picci P; Bacci G; Smeland S
Int J Oncol; 2006 Dec; 29(6):1459-68. PubMed ID: 17088985
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin.
Scotlandi K; Serra M; Manara MC; Lollini PL; Maurici D; Del Bufalo D; Baldini N
Int J Cancer; 1994 Jul; 58(1):95-101. PubMed ID: 7912235
[TBL] [Abstract][Full Text] [Related]
12. Relation between cellular doxorubicin binding ability to nuclear DNA and histologic response to preoperative chemotherapy in patients with osteosarcoma.
Kusuzaki K; Takeshita H; Murata H; Hirata M; Hashiguchi S; Ashihara T; Hirasawa Y
Cancer; 1998 Jun; 82(12):2343-9. PubMed ID: 9635526
[TBL] [Abstract][Full Text] [Related]
13. Expression profiles of osteosarcoma that can predict response to chemotherapy.
Man TK; Chintagumpala M; Visvanathan J; Shen J; Perlaky L; Hicks J; Johnson M; Davino N; Murray J; Helman L; Meyer W; Triche T; Wong KK; Lau CC
Cancer Res; 2005 Sep; 65(18):8142-50. PubMed ID: 16166288
[TBL] [Abstract][Full Text] [Related]
14. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
Hamada K; Tomita Y; Inoue A; Fujimoto T; Hashimoto N; Myoui A; Yoshikawa H; Hatazawa J
Ann Nucl Med; 2009 Jan; 23(1):89-95. PubMed ID: 19205843
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
McTiernan A; Meyer T; Michelagnoli MP; Lewis I; Whelan JS
Pediatr Blood Cancer; 2006 Mar; 46(3):345-50. PubMed ID: 16206197
[TBL] [Abstract][Full Text] [Related]
18. EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma.
Ferrari S; Bielack SS; Smeland S; Longhi A; Egerer G; Sundby Hall K; Donati D; Kevric M; Brosjö O; Comandone A; Werner M; Monge O; Palmerini E; Berdel WE; Bjerkehagen B; Paioli A; Lorenzen S; Eriksson M; Gambarotti M; Tunn PU; Jebsen NL; Cesari M; von Kalle T; Ferraresi V; Schwarz R; Bertulli R; Kasparek AK; Grignani G; Krasniqi F; Sorg B; Hecker-Nolting S; Picci P; Reichardt P
Tumori; 2018; 104(1):30-36. PubMed ID: 29218692
[TBL] [Abstract][Full Text] [Related]
19. Caffeine-potentiated chemotherapy for metastatic osteosarcoma.
Kimura H; Tsuchiya H; Shirai T; Nishida H; Hayashi K; Takeuchi A; Ohnari I; Tomita K
J Orthop Sci; 2009 Sep; 14(5):556-65. PubMed ID: 19802667
[TBL] [Abstract][Full Text] [Related]
20. Assessment of chemosensitivity in patients with malignant bone and soft tissue tumors using thallium-201 scintigraphy and doxorubicin binding assay.
Murata H; Kusuzaki K; Takeshita H; Hirata M; Hashiguchi S; Emoto K; Ashihara T; Hirasawa Y
Anticancer Res; 2000; 20(5C):3967-70. PubMed ID: 11268485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
